Please assess the completion status of the following clinical trial:

Trial Title: Capecitabine and Oxaliplatin in Treating Patients With Locally Advanced, Unresectable, or Metastatic Stomach Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically or cytologically confirmed gastric cancer~  * Locally advanced, unresectable, or metastatic disease~* Measurable disease, defined as at least 1 lesion that can be accurately measured in ≥ 1 dimension as ≥ 20 mm with conventional techniques or as ≥ 10 mm with spiral CT scan~* No known brain metastases~PATIENT CHARACTERISTICS:~* ECOG performance status (PS) 0-2 or Karnofsky PS 60-100%~* WBC ≥ 3,000/mm³~* Absolute neutrophil count ≥ 1,500/mm³~* Platelet count ≥ 100,000/mm³~* Bilirubin normal~* AST/ALT ≤ 2.5 times upper limit of normal~* Creatinine ≤ 1.5 mg/dL~* Not pregnant or nursing~* Negative pregnancy test~* Fertile patients must use effective contraception during study and for 6 months after completion of study treatment~* Able to swallow~* No history of allergic reactions attributed to compounds of similar chemical or biologic composition to fluoropyrimidines or platinum chemotherapy agents~* No uncontrolled intercurrent illness including, but not limited to the following:~  * Ongoing or active infection~ * Symptomatic congestive heart failure~ * Unstable angina pectoris~ * Cardiac arrhythmia~ * Psychiatric illness or social situations that would preclude study compliance~PRIOR CONCURRENT THERAPY:~* More than 4 weeks since prior chemotherapy or radiotherapy (6 weeks for nitrosoureas or mitomycin C) and recovered~* At least 6 months since prior radiotherapy with capecitabine as a radioenhancer~* No concurrent combination antiretroviral therapy for HIV-positive patients~* No other concurrent chemotherapy~* No concurrent palliative radiotherapy~* No concurrent hormonal therapy except for the following:~  * Steroids for adrenal failure~ * Hormones for nondisease related conditions (e.g., insulin for diabetes)~ * Intermittent use of dexamethasone as an antiemetic~* No other concurrent investigational agents~* No other concurrent anticancer agents or therapies

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 120 Years
- Healthy Volunteers: f

Study Arms:
- Oxaliplatin + Capecitabine (Type: EXPERIMENTAL): Patients will receive Oxaliplatin 85 mg/m2/d on day 1, given as a 2-hour infusion in 250 mL of dextrose 5% repeated every 2 weeks. Capecitabine will be administered orally at a dose of 850 mg/m2 twice a day.

Based on this trial design, predict the completion outcome and termination type (if applicable).